Tacoma, WA – According to filings with the U.S. Securities and Exchange Commission, Revalesio is raising $15,003,000.00 in new funding. Sources indicate as part of senior management President, Greg Archambeau played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Revalesio
Revalesio is a clinical-stage pharmaceutical company committed to creating treatments for neurological diseases and conditions that lack adequate therapeutic options. Our therapies address cellular imbalances related to mitochondrial dysfunction and thereby modulate the immune response. They have been shown to protect neurons in models of chronic neurological diseases and improve recovery in acute neurological injury. We are partnering with internationally renowned scientists in biomedical research in a concerted effort to improve the lives of millions.

To learn more about Revalesio, visit http://revalesio.com/

Contact:
Greg Archambeau, President
253-922-2600
garchambeau@revalesio.com
https://www.linkedin.com/in/greg-archambeau-4394a71a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved